

Allwellness Holdings Group Limited (Formerly known as Allwellness Pharmaceutical Pty Limited)

ABN: 42 604 613 050

Financial Report For the Half Year Ended 31 December 2016

Walker Wayland NSW
Chartered Accountants
Sydney, New South Wales

ABN 42 504 613 050

DIRECTORS' REPORT

Your directors present their financial report on the consolidated entity ("group") for the half year ended 31 December 2016.

Directors

The name of the directors in office at any time during or since the end of the year is:

Mr Yong Zhang (appointed 6 March 2015)

Mr Chen Wang (appointed 1 December 2016)

Mr Yilong Shan (appointed 1 December 2016)

Review of Operations and Financial Results

The loss of the consolidated entity for the half year ended 31 December 2016 after providing for income tax amounted to \$39,106 (2015; Loss of \$105,012)

On 7 December 2016, the company raised capital via the issue of 740,865 shares at \$1 each raising a total of \$740,865.

Principal Activities

The principal activities of the group during the half year ended 31 December 2016 included exporting health care products to China.

There has been no significant change in the nature of these activities during the period.

Events Subsequent to the End of the Reporting Period

No matters or circumstances have arisen since the end of the half year ended 31 December 2016 which significantly affected or may significantly affect the operations of the group, the results of those operations, or the state of affairs of the group in future financial years.

Auditors' Independence Declaration

A copy of the auditors' independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 2.

Mr Yong Zhang

Signed in accordance with a resolution of the Board of Directors:

Director

ted this Clay of March 2017

1





ABN 55 931 152 366

Level 11, Suite 11.01 60 Castlereagh Street SYDNEY NSW 2000

GPO Box 4836 SYDNEY NSW 2001

Telephono: 161 2 9951 5400 Facsimile: +61 2 9951 5454 mail@wwnsw.com.au

Website: www.wwnsw.com.au

AUDITORS' INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF ALLWELLNESS HOLDINGS GROUP LIMITED (FORMERLY KNOWN AS ALLWELLNESS
PHARMACEUTICAL PTY LIMITED)

We declare that, to the best of our knowledge and belief, during the half year ended 31 December 2016 there have been:

- no contraventions of the auditors' independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the review.

Walker Wayland NSW

Chartered Accountants

Wali Aziz

Principal

Dated this 13th day of April 2017

ABN 42 604 613 050

CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF YEAR PERIOD ENDED 31 DECEMBER 2016

	Note	Consolidated Group	
		December 2016 \$	December 2015 \$
Sales revenue		80,360	: -
Less: Cost of sales		(49,014)	: : -
Gross profit	***	31,346	
Interest revenue		759	: : ••
Administration expenses	2	(71,211)	(105,012)
(Loss) before income tax	Personal Per	(39,106)	(105,012)
Income tax expense		***	
(Loss) for the year	***	(39,106)	(105,012)
Total comprehensive loss for the year		(39,106)	(105,012)
Total comprehensive loss attributable to members of the parent entity	A right	(39,106)	(105,012)
	· Gra	STATE OF THE PROPERTY OF THE P	ATOMORPH IN THE TOTAL PROPERTY OF THE PARTY

ABN 42 604 613 050

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2016

	Note	Consolidated Group	
		As at 31 December 2016	As at 30 June 2016
		\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	3	760,021	52,810
Inventories		145,546	171,679
Other assets		40,864	45,284
TOTAL CURRENT ASSETS		946,431	269,773
NON-CURRENT ASSETS			- 1
Intangible assets		4,113	2,003
TOTAL NON-CURRENT ASSETS		4,113	2,003
TOTAL ASSETS		950,544	271,776
LIABILITIES		- ANT	(1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-
CURRENT LIABILITIES			
Trade and other payables		10,000	1,288
TOTAL CURRENT LIABILITIES		10,000	1,288
NON-CURRENT LIABILITIES		AND THE PROPERTY OF THE PROPER	
Financial liabilities	4	342,491	374,194
TOTAL NON-CURRENT LIABILITIES		342,491	374,194
TOTAL LIABILITIES		352,491	375,482
NET ASSETS / (LIABILITIES)		598,053	(103,706)
EQUITY		Sasuukumaunusuuunusukkauusunininin	audunamahumudada peresikasi
Issued capital	5	740,866	1
Accumulated losses		(142,813)	(103,707)
TOTAL EQUITY		598,053	(103,706)
			orioni di tassimi indiangana nimasa i

ABN 42 604 613 050

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE HALF YEAR PERIOD ENDED 31 DECEMBER 2016

	Ordinary	Accumulated losses	Total
	\$	\$	\$
Balance at 1 July 2015	1	(5,201)	(5,200)
Loss for the period	44	(105,012)	(105,012)
Balance at 31 December 2015	1	(110,213)	(110,212)
Balance at 1 July 2016	1	(103,707)	(103,706)
Issue of shares	740,865	175	740,865
Loss for the period	×.	(39,106)	(39,106)
Balance at 31 December 2016	740,866	(142,813)	598,053

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR PERIOD ENDED 31 DECEMBER 2016

• .	Note	Consolidated Group	
		Period ended 31 December 2016 \$	Period ended 31 December 2015 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		80,360	
Payments to suppliers and employees		(80,669)	(85,278)
Interest received		759	
Net cash used in operating activities		450	(85,278)
CASH FLOWS FROM INVESTING ACTIVITIES		***************************************	996484493846485643 (5919544114 3) (************************************
Payment for non-current assets		(2,400)	**
Net cash (used) in investing activities		(2,400)	neigy steel became the areas to subject to the subj
CASH FLOWS FROM FINANCING ACTIVITIES		reamentary and engages and elementary break provident in the common provident	non-ye conflicted the control of the
Issue of shares		740,865	
Loans from related parties		··· , · · · ·	89,000
Repayment of loans to related party		(31,704)	
Net cash provided by financing activities		709,161	89,000
Net Increase in cash held		707,211	3,722
Cash at beginning of financial year		52,810	16,534
Cash at end of financial year	-	760,021	20,256

ABN 42 604 613 050

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF YEAR PERIOD ENDED 31 DECEMBER 2016

The consolidated financial statements and notes represent those of Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited) (the "Consolidated Group" or "Group").

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation

These general purpose financial statements for the half-year reporting period ended 31 December 2016 have been prepared in accordance with the requirements of AASB 134 Interim Financial Reporting and the Corporations Act 2001. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 Interim Financial Reporting. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2016, together with any public announcements made during the following half year in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements except to the matters discussed below.

These financial statements were authorised for issue by the board of directors on 31 March 2017

Accounting Policies

a. Going Concern Basis of Accounting

The financial statements have been prepared on a going concern basis. The group incurred a net loss of \$39,106 for the period ended 31 December 2016 (2015: Loss of \$105,012). As at that date, the group had a net asset position of \$598,053 (30 June 2016 Net liabilities \$103,706).

On 7 December 2016 Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited) raised capital via the issue of 740,865 shares at \$1 each raising a total of \$740,865. Further to that, Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited) is dependent on the ongoing support of the directors to provide funds, accordingly a letter of support has been obtained. Further to the above, the directors have signed a distribution agreement post half year end that will generate potential sales of approximately \$1 million for the year ended 31 December 2017. Based on this management and board are of the opinion that the operations of the Group are viable and can continue a going concern.

ABN 42 604 613 050

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF YEAR	PERIOD ENDED 31 D	ECEMBER 2016	
	Consolidated Group		
	Period ended 31 December 2016 \$	Period ended 31 December 2015 \$	
NOTE 2: LOSS BEFORE INCOME TAX			
Loss before income tax includes the following expenses:		i	
a. Expenses			
Depreciation expense	290	290	
Rental Expense	19,486	13,872	
	19,776	14,162	
	Period ended 31 December 2016	Year Ended 30 June 2016	
	\$	\$	
NOTE 3: CASH AND CASH EQUIVALENTS			
Cash on hand	2	2	
Cash at bank	760,019	52,808	
	760,021	52,810	
NOTE 4: FINANCIAL LIABILITIES NON-CURRENT	The state of the s	The state of the s	

The loan is unsecured and has been provided on interest free terms. The director has agreed in writing not to recall the loan within 12 months

NOTE 5: ISSUED CAPITAL

Interest free loan provided by director

Deposit from shareholders for future share issue

Ordinary Shares	Number of shares	\$
Fully paid ordinary shares as at 30 June 2016	1	1
Share split on 7 December 2016 (1 share split into 1,759,135 shares)	1,759,135	4
Issue of 740,865 shares at an issue price of \$1 each on 7 December 2016	740,865	740,865
Total number of shares as at 31 December 2016	2,500,000	740,866

342,491

342,491

334,214

39,980

374,194

Ordinary shares participate in dividends and the proceeds on winding up of the group in proportion to the number of shares held.

At the shareholders' meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

ABN 42 604 613 050

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF YEAR PERIOD ENDED 31 DECEMBER 2016

NOTE 6: EVENTS AFTER THE BALANCE SHEET DATE

No matters or circumstances have arisen since the end of the half year period which significantly affected or may significantly affect the operations of the group, the results of those operations, or the state of affairs of the group in future financial years.

		Period ended 31 December 2016 \$	Year Ended 30 June 2016
NOTE 7: RELATED PARTY TRANSACTIONS			
Transactions with related parties:			
Interest free loan provided by director	4	342,491	334,214
Deposit from shareholders for future share issue			39,980
		342,491	374,194
		342,491	374,194

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

NOTE 8: SEGMENT REPORTING

The consolidated entity operates in the exporting of health care products business segment within China.

NOTE 9: CONTINGENT LIABILITIES

There are no contingent assets or contingent liabilities as at the date of this report.

NOTE 10: COMPANY DETAILS

The registered office of the company is:

Unit 21

5 Hudson Avenue

Castle Hill, NSW, Australia, 2154

The principal place of business is:

Unit 21

5 Hudson Avenue

Castle Hill, NSW, Australia, 2154

ABN 42 604 613 050

DIRECTORS' DECLARATION

In accordance with a resolution of the directors of Allweliness Holdings Group Limited Allweliness (formerly known as Allweliness Pharmaceutical Pty Limited), the Directors of the company declare that:

- 1. The financial statements and notes, as set out on pages 3 to 8 are in accordance with:
 - a. Accounting Standard AASB 134 Interim Financial Reporting, other mandatory professional reporting requirements; and
 - b. giving a true and fair view of the Group's financial position as at 31 December 2016 and of its performance, for the half-year ended on that date; and
- 2. there are reasonable grounds to believe that Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited) will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.

Director

Dated this 31 day of March 2017

9





ABN 55 931 152 366

Level 11, Suite 11.01 60 Castlereagh Street SYDNEY NSW 2000

GPO Box 4836 SYDNEY NSW 2001

Telephone: +61.2 9951 5400 Facsimile: +61.2 9951 5454 mail@wwnsw.com.au

Website: www.wwnsw.com.au

INDEPENDENT AUDITORS' REVIEW REPORT TO THE MEMBERS OF ALLWELLNESS HOLDINGS GROUP LIMITED (FORMERLY KNOWN AS ALLWELLNESS PHARMACEUTICAL PTY LIMITED)

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited) and its Controlled Entity which comprises the consolidated statement of financial position as at 31 December 2016, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the Company and the entity it controlled at the half-year end or from time to time during the financial period.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with AASB 134 Interim Financial Reporting including: giving a true and fair view of the consolidated entities financial position as at 31 December 2016 and its performance for the half-year ended on that date. As the auditor of Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited) ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





ABN 55 931 152 366

Level 11, Suite 11,01 60 Castlereagh Street SYDNEY NSW 2000

GPO Box 4836 SYDNEY NSW 2001

Telephone: +61/2 9951 5400 Facsimile: +61/2 9951 5454 mail@wwnsw.com.au

Website: www.wwnsw.com.au

INDEPENDENT AUDITORS' REVIEW REPORT TO THE MEMBERS OF ALLWELLNESS HOLDINGS GROUP LIMITED (FORMERLY KNOWN AS ALLWELLNESS PHARMACEUTICAL PTY LIMITED)

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of Allwellness Holdings Group Limited (formerly known as Allwellness Pharmaceutical Pty Limited), would be in the same terms if given to the directors as at the time of this auditor's report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of name of company is not in accordance with AASB 134 Interim Financial Reporting, including giving a true and fair view of the company financial position as at 31 December 2016 and of its performance for the half-year ended on that date.

Walker Wayland NSW

Chartered Accountants

Wali Aziz

Principal

Dated this 13th day of April 2017

Suite 11.01, Level 11, 60 Castlereagh Street, Sydney NSW 2000